Diametric Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Diametric Capital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-43,771	Closed	-$328K	–	475
2024 Q2	$328K	Buy	43,771 +21,001	+92%	+$183K	0.18%	164
2024 Q1	$227K	Sell	22,770 -41,864	-65%	-$466K	0.13%	224
2023 Q4	$637K	Sell	64,634 -71,697	-53%	-$511K	0.39%	78
2023 Q3	$1.04M	Buy	136,331 +16,425	+14%	+$164K	0.44%	56
2023 Q2	$896K	Buy	+119,906	New	+$839K	0.4%	64
2022 Q3	–	Sell	-35,665	Closed	-$290K	–	325
2022 Q2	$290K	Buy	+35,665	New	+$239K	0.21%	160

Other funds holding RXRX

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Diametric Capital's RXRX Position: Q3 2024 in Review

Diametric Capital sold out of Recursion Pharmaceuticals (RXRX) in Q3 2024, closing a stake of 43,771 shares — an estimated $328K sold.

Diametric Capital first reported a position in RXRX in Q2 2022 and held it in 6 quarters. The position peaked at $1.04M in Q3 2023. 267 funds tracked by Wall St. Rank hold RXRX as of Q3 2024.

Diametric Capital reported no remaining Recursion Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Diametric Capital sold 43,771 Recursion Pharmaceuticals shares in Q3 2024, an estimated $328K.
Diametric Capital first reported a position in Recursion Pharmaceuticals in Q2 2022 and held it in 6 quarters.
Diametric Capital's Recursion Pharmaceuticals position peaked at $1.04M in Q3 2023.
267 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2024.

Based on Diametric Capital's 13F filing for Q3 2024, filed 13 Nov 2024.